NRX Pharmaceuticals
NRXP
24 hedge funds and large institutions have $13M invested in NRX Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 5 closing their positions.
29,000% more call options, than puts
Call options by funds: $582K | Put options by funds: $2K
300% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 3
34% more capital invested
Capital invested by funds: $9.76M → $13M (+$3.28M)
4.62% more ownership
Funds ownership: 15.35% → 19.97% (+4.6%)
4% less funds holding
Funds holding: 25 → 24 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.2M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$446K |
| 3 |
Renaissance Technologies
New York
|
+$367K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$237K |
| 5 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$224K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$264K |
| 2 |
Squarepoint
New York
|
-$138K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$8.9K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
-$8.38K |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
-$2.55K |
NRXP Hedge Fund Activity: Q3 2025 in Review
24 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q3 2025, worth a combined $13M — up 34% from $9.76M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NRXP and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 12 added.
The largest buyer was Anson Funds Management, adding an estimated $1.2M. The largest seller was Citadel Advisors, exiting entirely with an estimated $264K sold.
- 24 institutional investors held NRX Pharmaceuticals (NRXP) as of Q3 2025, down from 25 in Q2 2025.
- Funds reported $13M of NRX Pharmaceuticals stock for Q3 2025, up 34% quarter-over-quarter.
- 4 funds opened new NRX Pharmaceuticals positions in Q3 2025 and 5 closed out, a net change of -1 holder.
- The largest NRX Pharmaceuticals buyer in Q3 2025 was Anson Funds Management, an estimated $1.2M added.
- The largest NRX Pharmaceuticals seller in Q3 2025 was Citadel Advisors, an estimated $264K sold.
Based on aggregated 13F filings for Q3 2025.